Evidence map›Paper›PMID 19048633›Full record

ArticleGenetic epidemiology2009

The limits of fine-scale mapping.

Lucian P Smith, Mary K Kuhner

Abstract read
In one paragraph

Article in Genetic epidemiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lucian P SmithDepartment of Genome Sciences, University of Washington, Seattle, WA 98195-5065, USA. lpsmith@u.washington.edu
Mary K Kuhner

Funding

Selection and Association in Coalescent GenealogiesR01GM051929 · NIGMS · UNIVERSITY OF WASHINGTON · PI KUHNER, MARY K · 1995 to 2006
$2.6M
NIGMS NIH HHS GM 51929-10NIGMS NIH HHS R01 GM051929
6 · The paper itself

Abstract

When a novel genetic trait arises in a population, it introduces a signal in the haplotype distribution of that population. Through recombination that signal's history becomes differentiated from the DNA distant to it, but remains similar to the DNA close by. Fine-scale mapping techniques rely on this differentiation to pinpoint trait loci. In this study, we analyzed the differentiation itself to better understand how much information is available to these techniques. Simulated alleles on known recombinant coalescent trees show the upper limit for fine-scale mapping. Varying characteristics of the population being studied increase or decrease this limit. The initial uncertainty in map position has the most direct influence on the final precision of the estimate, with wider initial areas resulting in wider final estimates, though the increase is sigmoidal rather than linear. The Theta of the trait (4Nmu) is also important, with lower values for Theta resulting in greater precision of trait placement up to a point--the increase is sigmoidal as Theta decreases. Collecting data from more individuals can increase precision, though only logarithmically with the total number of individuals, so that each added individual contributes less to the final precision. However, a case/control analysis has the potential to greatly increase the effective number of individuals, as the bulk of the information lies in the differential between affected and unaffected genotypes. If haplotypes are unknown due to incomplete penetrance, much information is lost, with more information lost the less indicative phenotype is of the underlying genotype.

Indexed as

Quantitative Trait LociChromosome MappingEpidemiologic MethodsGenetics, PopulationHumansLikelihood FunctionsLinkage DisequilibriumModels, GeneticMutationPenetrancePolymorphism, Single NucleotidePopulation DensityRecombination, GeneticSample SizeSoftware

Identifiers

PMID19048633
PMCPMC2707455

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.